Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
18 March 2013 |
Main ID: |
EUCTR2008-001405-41-DE |
Date of registration:
|
28/08/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX
|
Scientific title:
|
A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX |
Date of first enrolment:
|
24/10/2008 |
Target sample size:
|
|
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001405-41 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product:
Placebo:
Other:
|
Phase:
|
|
|
Countries of recruitment
|
Germany
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Untreated patients with systemic AL amyloidosis - Age between 18 and 74 years - Not eligible for or refused high-dose chemotherapy - NYHA stage < IV - Measurable plasma cell disorder
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: - Multiple myeloma stage II and III - Not able to visit the Amyloidosis Clinic in Heidelberg once per months - Pregnant or breast feeding females - Not able to give informed consent
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
AL amyloidosis
|
Intervention(s)
|
Trade Name: Revlimid Pharmaceutical Form: Capsule* Other descriptive name: Lenalidomide Concentration unit: IU/mg international unit(s)/milligram Concentration number: 5 mg-
Trade Name: Alkeran Product Code: L01AA03 Pharmaceutical Form: Film-coated tablet Other descriptive name: melphalan Concentration unit: IU/mg international unit(s)/milligram Concentration number: 2 mg-
Trade Name: Fortecortin Pharmaceutical Form: Tablet Other descriptive name: dexamethasone Concentration unit: IU/mg international unit(s)/milligram Concentration number: 4 mg-
|
Primary Outcome(s)
|
Main Objective: Evaluate rate of complete remission
|
Secondary Objective: toxicity, rate of haematological response and organ response, correlation of cytogenetic aberrations and GEP results with haematological response, retrospective comparison with historical controls treated with M-Dex
|
Primary end point(s): CR rate after 6 cycles of L-M-Dex
|
Secondary ID(s)
|
GMIHO-005/2007 (191063)
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|